CSIMarket
 
Insulet Corporation  (PODD)
Other Ticker:  
 
 
Price: $169.2500 $5.25 3.201%
Day's High: $170.6128 Week Perf: 0.25 %
Day's Low: $ 162.01 30 Day Perf: -11.33 %
Volume (M): 1,500 52 Wk High: $ 335.91
Volume (M$): $ 253,790 52 Wk Avg: $232.26
Open: $163.65 52 Wk Low: $125.82



 Market Capitalization (Millions $) 11,876
 Shares Outstanding (Millions) 70
 Employees 3,500
 Revenues (TTM) (Millions $) 1,697
 Net Income (TTM) (Millions $) 206
 Cash Flow (TTM) (Millions $) 15
 Capital Exp. (TTM) (Millions $) 109

Insulet Corporation
Insulet Corporation is a medical technology company that was founded in 2000 and is headquartered in Acton, Massachusetts. The company specializes in developing and manufacturing insulin delivery systems for people with diabetes.

One of Insulet Corporation's main products is the Omnipod insulin management system, which is a tubeless, wearable insulin pump that delivers continuous insulin for people with Type 1 diabetes. The Omnipod system consists of two components: a pod that is worn on the body and a handheld device that is used to control the pod.

The Omnipod system is unique in that it is wireless and completely tubeless, making it more discreet and flexible than other insulin pumps on the market. The system also uses a proprietary algorithm that adjusts insulin delivery based on a user's glucose levels in real-time, making it more precise and effective for managing diabetes.

In addition to the Omnipod system, Insulet Corporation also offers a range of accessories and supplies to help people with diabetes manage their insulin therapy. These include test strips, lancets, and glucose meters.

Insulet Corporation is committed to innovation and is constantly developing new products and technologies to improve the lives of people with diabetes. The company has a team of engineers, scientists, and healthcare professionals who work together to research, develop, and bring new products to market.

Overall, Insulet Corporation is a leading medical technology company that is dedicated to helping people with diabetes manage their condition more effectively and efficiently. Their innovative products and commitment to patient care have made them a trusted name in the diabetes community.


   Company Address: 100 Nagog Park Acton 1720 MA
   Company Phone Number: 600-7000   Stock Exchange / Ticker: NASDAQ PODD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Insulet Corporation

Insulet Corporation Reports Record-Breaking Financial Performance in Fourth Quarter of 2023

Insulet Corporation (NASDAQ: PODD), a global leader in tubeless insulin pump technology, has reported impressive financial results for the period of October to December 31, 2023. The company's EPS soared by a remarkable 406.92% to $1.22 per share compared to the previous year, while revenue grew by 37.896% to $509.80 million.
One interesting fact to note is that Insulet Corporation's revenue growth outpaced that of its industry peers. In the fourth quarter of 2023, the company experienced a revenue advance of 7.82%, while the average growth for the Medical Equipment & Supplies sector was only 7.82% from the same period the previous year.

Product Service News

Insulet and Abbott Unite to Transform Diabetes Management: Omnipod 5 Receives CE Mark Approval for Integration with FreeStyle Libre 2 Plus Sensor

Published Wed, Feb 7 2024 11:00 AM UTC

Insulet's Omnipod 5 Receives CE Mark Approval for Integration with Abbott FreeStyle Libre 2 Plus Sensor: A Major Breakthrough for Type 1 Diabetes Management ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the renowned leader in tubeless insulin pump technology with its Omnipod brand, announced a significant development today. The Company has successfully obtained CE mark ...

Management Changes

Insulet Corporation Strengthened with New Board Appointments and Retirements, Aims to Steer Financial Stability and Drive Growth

Published Thu, Jan 18 2024 9:01 PM UTC

Insulet Announces Changes to Board of Directors with Retirements and New Appointments
ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, is proud to announce significant changes to its Board of Directors. These changes, effective January 18, reflect the company's commitment to exper...

Insulet Corporation

Insulet Corporation Surges Ahead with Record-breaking Revenue Rise, Reaching Profitability Milestone in Q3 2023

Insulet Corporation Reports Strong Revenue Rise and Turns Profitable in Q3 2023
ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, announced impressive financial results for the third quarter ending September 30, 2023. The company reported a significant increase in revenue, which resulted in it turning profitable during this period.
Insulet Corporation witnessed a remarkable 26.966% rise in revenue, reaching $432.70 million in Q3 2023. This substantial growth in revenue contributed to the company's profitability, with earnings per share (EPS) standing at $0.74. Comparatively, in the previous financial interval ending September 30, 2022, the company reported negative EPS of $-0.08.

Insulet Corporation

Astonishing Second Quarter Rebound: Insulet Corporation's EPS Soars to $0.39, Defying Stock's Recent Dip

During the past 5 trading days, shares of Insulet Corporation experienced a significant decrease, dropping by -13.64%. This decline compounds the company's year-to-date performance, which now stands at -21.34%. However, despite this recent decrease, Insulet's stock is still trading 8% above its 52-week low.
This downward trend in the stock's price is puzzling when considering the company's positive financial performance in the second quarter of 2023. Insulet reported a notable turnaround in its income, with earnings per share (EPS) rising to $0.39 compared to a loss per share of $0.50 in the same period a year earlier. This represents a substantial increase of 14.71% in EPS compared to the prior reporting period, where it stood at $0.34 per share.






 

Insulet's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Insulet does not provide revenue guidance.

Earnings Outlook
Insulet Corporation does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com